ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001

Also written as “SKB264+SKB118”, “CR-001” and “SKB118 Injection”.

Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageAnti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since May 7, 20264 company-led studies, 4 open or runningNext primary completion: Dec 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Kelun Pharmaceuticalits history only33 open or runningphase 2since May 7, 2026May 7, 2026Dec 30, 2027phase 2 · NCT07854509
Crescent Biopharmaits history only11 open or runningphase 2since Jan 8, 2026Jan 8, 2026Feb 2029phase 2 · NCT07335497

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2026First study: phase 2 study in Neoplasm MetastasisNew to Crescent BiopharmaCrescent Biopharma · NCT07335497 · 540 planned · United States, Australia, France and more
  2. May 7, 2026Sichuan Kelun Pharmaceutical’s first study: phase 2 study in Advanced Solid TumorsNew to Sichuan Kelun PharmaceuticalSichuan Kelun Pharmaceutical · NCT07586943 · 530 planned · China
  3. Jul 3, 2026Phase 2 study in NSCLCSichuan Kelun Pharmaceutical · NCT07697586 · 206 planned · China
  4. Sep 28, 2026Phase 2 study in Non-Squamous Non-Small Cell Lung CancerSichuan Kelun Pharmaceutical · NCT07854509 · 110 planned

Ahead

  1. Dec 30, 2027Primary completion: phase 2 study in Non-Squamous Non-Small Cell Lung CancerSichuan Kelun Pharmaceutical · NCT07854509
  2. Aug 2028Primary completion: phase 2 study in NSCLCSichuan Kelun Pharmaceutical · NCT07697586
  3. Feb 2029Primary completion: phase 2 study in Neoplasm MetastasisCrescent Biopharma · NCT07335497
  4. Dec 2029Primary completion: phase 2 study in Advanced Solid TumorsSichuan Kelun Pharmaceutical · NCT07586943

TargetBeta

PDCD1 →VEGFA →read by rule
“A tetravalent bispecific antibody consisting of a bivalent, Fc-silenced, immunoglobulin G1 (IgG1) antibody targeting human vascular endothelial growth factor A (VEGF-A), with two single chain variable fragments (scFvs) targeting the negative immunoregulatory human cell receptor programmed cell death”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07854509Non-Squamous Non-Small Cell Lung Cancer2Not yet recruitingSichuan Kelun PharmaceuticalDec 30, 2027110
NCT07697586NSCLC · China2RecruitingSichuan Kelun PharmaceuticalAug 2028206
NCT07586943Advanced Solid Tumors · China2RecruitingSichuan Kelun PharmaceuticalDec 2029530
NCT07335497Neoplasm Metastasis · United States, Australia, France and more2RecruitingCrescent BiopharmaFeb 2029540

How it is read

Names in the registry

  • “SKB264+SKB118”, 2 entries
  • “CR-001”, 1 entry
  • “SKB118 Injection”, 1 entry
  • “SKB118+SKB264”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.